Prostate Cancer Clinical Trial
Official title:
Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
NCT number | NCT01492972 |
Other study ID # | GU003-10 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | January 2012 |
Verified date | May 2024 |
Source | Proton Collaborative Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy.
Status | Recruiting |
Enrollment | 192 |
Est. completion date | |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed prostate adenocarcinoma (within 365 days of randomization) at intermediate risk for reoccurrence determined by at least one of the following: Gleason Score 7, PSA > = 10 and < = 20, T stage T2b - T2c - Clinical stages T1-T2c N0 M0 as staged by the treating investigator. (AJCC Criteria 7th Ed.- appendix III). - Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason score must be in the range of 2-7. > 6 cores are strongly recommended. - PSA values < = 20 ng/ml within 90 days prior to randomization. Obtained prior to biopsy or at least 21 days after prostate biopsy. - ECOG performance status 0-1 (appendix II) assessed within 90 days of randomization. - Patients must sign IRB approved study specific informed consent. - Patients must complete all required pre-entry tests listed in section 4.0 within the specified time frames. - Patients must be able to start treatment within 56 days of randomization. - Patients must be at least 18 years old. - For brachytherapy, an IPSS = 21, or = 17 if patient is on medications to improve urination. - For brachytherapy, prostate volume must be less than 55cc prior to AS. Exclusion Criteria: - Pelvic lymph nodes > 1.5 cm in greatest dimension unless the enlarged lymph node is biopsied and negative. - Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery. - Previous pelvic radiation for prostate cancer. - Previous androgen suppression therapy for prostate cancer. - Active rectal diverticulitis, Crohn's disease affecting the rectum or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed). - Prior systemic chemotherapy for prostate cancer. - History of proximal urethral stricture requiring dilatation. - Current and continuing anticoagulation with warfarin sodium (Coumadin), heparin, low- molecular weight heparin, Clopidogrel bisulfate (Plavix), or equivalent (unless it can be stopped to manage treatment related toxicity or to have a biopsy if needed). - Major medical, addictive or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (Consent by legal authorized representative is not permitted for this study). - Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed). - History of myocardial infarction within the last 6 months. |
Country | Name | City | State |
---|---|---|---|
United States | Hampton University Proton Therapy Institute | Hampton | Virginia |
United States | Oklahoma Proton Center | Oklahoma City | Oklahoma |
United States | Mayo Clinic | Scottsdale | Arizona |
United States | Northwestern Medicine Chicago Proton Center | Warrenville | Illinois |
Lead Sponsor | Collaborator |
---|---|
Proton Collaborative Group |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Morbidity Outcomes | To determine if androgen suppression along with radiation therapy will result in a higher freedom from failure (FFF) than radiation therapy without androgen suppression. Freedom from failure (FFF): The events for FFF will be the first occurrence of clinical failure (local recurrence, regional recurrence, or distant metastasis), biochemical failure by the Phoenix definition (PSA = 2 ng/ml over the current nadir PSA) (45) discounting bounces per investigator discretion, or the start of salvage therapy including androgen suppression |
after the initial 100 patients have had a median follow up of at least three years and then every year. | |
Secondary | Frequency and severity of grade 2 or higher GU and GI toxicity | Assessment of grade 2 or higher GU and GI toxicity using CTCAE 4.0 criteria | At 6 months | |
Secondary | Frequency and severity of GI and GU toxicity | At 3 years | ||
Secondary | Incidence of quality of life issues | At completion of radiation therapy | ||
Secondary | Incidence of Freedom from biochemical failure (FFBF) | At 5 years | ||
Secondary | Incidence of clinical failure: local and/or distant | At 5 years | ||
Secondary | Incidence of salvage Androgen Suppression use (SAD) | At 5 years | ||
Secondary | Incidence of progression free survival: using clinical, biochemical and SAD as events | At 5 years | ||
Secondary | Incidence of overall survival | At 5 years | ||
Secondary | Incidence of disease-specific survival | At 5 years | ||
Secondary | Correlate pathologic and radiologic findings with outcomes | At 5 years | ||
Secondary | Correlate PSA and free PSA levels with outcomes | At 5 years | ||
Secondary | Correlate testosterone levels and variation with proton therapy and outcomes | At 5 years | ||
Secondary | Prospectively collect information that will help to define dose-volume relationships of normal structures with acute and chronic toxicity | At 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |